ClinicalTrials.gg
CompletedNCT00121719Updated Jun 22, 2023Results posted

An Open Label Dose Escalation Study Of E7080

A Phase 1 interventional study of Lenvatinib in Solid Tumor or Lymphoma, sponsored by Eisai Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 72 studies in Lymphoma with a site in Netherlands — 8 open to participants now, 19 under way, 8 of them phase 3. Lymphoma · Netherlands.

Enrollment
42nd of 67
82 · median 119
Started
2005
with 1 other
Phase 1
10 of 72
1 open now
Registered
23rd of 72
by date
Lead sponsor
2 of 72
Eisai Inc.

Among the 72 studies in Lymphoma with a site in Netherlands, this one is the 42nd largest by enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2005, is one of 10 in phase 1, and was the 23rd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

8 of the 72 studies in Lymphoma with a site in Netherlands are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Lymphoma with a site in Netherlands, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.

Read the detailed description

This is an open-label, non-randomized, dose escalation study. Patients will be treated with lenvatinib once daily. Each four-week treatment period will be considered to be one treatment cycle. The selection of subsequent dose levels will be performed according to an accelerated design: Although initially 3 patients per dose level will be entered, the next dose level can be opened for patient accrual after only the first patient in the previous cohort completes Cycle 1 with no drug-related toxicity greater than grade 1 (except alopecia, lymphopenia and anemia).

03

Conditions studied

  • Solid Tumor or Lymphoma

Keywords

  • Resistant and refractory solid tumors
  • lymphomas
  • hodgkins disease
  • non-hodgkins lymphoma
  • neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the inclusion criteria outlined below in order to be eligible to participate in the study:

  1. Patients with and/or cytologically confirmed solid tumor or lymphoma who are resistant/ to approved therapies or for whom no appropriate therapies are available.
  2. All previous treatment (including surgery and radiotherapy) must have been completed at least four weeks prior to study entry and any acute toxicities must have resolved.
  3. Aged greater than or equal to 18 years.
  4. performance status greater than or equal 70%.
  5. Written to participate in the study.

Exclusion criteria

EXCLUSION CRITERIA:

Patients with the following characteristics will not be eligible for the study:

  1. Brain tumors or brain or .
  2. Any of the following laboratory parameters:

    1. less than 9 g/dl (5.6 mmol/L)
    2. neutrophils less than 1.5 x 10\^9/L
    3. less than 100 x 10\^9/L
    4. serum greater than 25 micro-mol/l (1.5 mg/dl)
    5. other liver parameters greater than 3 x the (ULN)
    6. serum creatinine greater than 1.5 x ULN or less than 60 ml/minute
  3. Uncontrolled infections.
  4. cardiac impairment or unstable ischemic heart disease including a myocardial infarction within six months of study start.
  5. Any treatment with drugs within 30 days before the start of the study.
  6. Pregnancy or lactation (all women of must have a negative pregnancy test before inclusion in the study; women must be amenorrheic for at least 12 months). Female patients of childbearing potential must use adequate protection, defined as two forms of contraception, one of which must be a barrier method.
  7. Fertile males not willing to use contraception or whose female partners are not using adequate contraceptive protection.
  8. History of alcoholism, drug addiction, or any psychiatric or psychological condition which, in the opinion of the investigator, would impair study compliance.
  9. Legal incapacity.
  10. Centrally located or squamous cell carcinoma of the lung.
  11. Proteinuria greater than 1+ on bedside testing.
  12. History of gastrointestinal malabsorption.
  13. Surgery involving gastro- and/or intestinal anastomosis within four weeks of study start.
  14. Patients with bleeding or thrombotic disorders.
  15. Patients using therapeutic dosages of anticoagulants.
  16. Poorly controlled hypertension (defined as a change in hypertensive therapy within three months of study start) or patients diagnosed with hypertension (defined as a repeat blood pressure measurement of 160/90 mmHg or higher) at screening.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    1

    Drug: Lenvatinib

Interventions

  • Lenvatinib tablets taken orally, once daily.

    Also known as: E7080

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    The MTD was defined as the highest dose level at which no more than one out of six participants experienced dose-limiting toxicity (DLT). DLT was assessed during the first 4 weeks of therapy (Cycle 1) for dose escalation purposes. Participants enrolled into the MTD cohort were given the option to also participate in the food-effect pilot study. The food-effect pilot study was initiated once the MTD had been established.

    Time frame: Cycle 1 (4 weeks)

Secondary outcomes

  1. Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    All AEs were graded on a 5-point scale according to the National Cancer Institute's Common Toxicity Criteria (NCI CTC) grading system, version 3.0. Safety was assessed using the occurrence of DLTs, AEs, SAEs, clinical laboratory test results, vital signs measurements, physical examination findings, and electrocardiograms (ECGs) readings. An AE was defined as any untoward medical occurrence in a participant administered lenvatinib and did not necessarily have a causal relationship to lenvatinib. An SAE was defined as any untoward medical occurrence which results in death, was life-threatening, required hospitalization or prolonged hospitalization, resulted in persistent or significant disability/incapacity, or caused a congenital anomaly/birth defect. Treatment-related AEs and SAEs are AEs considered probably or possibly related to lenvatinib.

    Time frame: First date of study treatment to date of last dose of study treatment, up to approximately 13 years and 8 months

  2. Dose-limiting Toxicities (DLTs)

    A DLT was defined as any grade 3 or higher hematological or non-hematological toxicity directly related to lenvatinib, any repeated National Cancer Institute Common Toxicity Criteria (NCI CTC) grade 2 hematological or non-hematological toxicity considered to be directly related to lenvatinib and required dose reduction, or failure to administer greater than or equal to 75% of the planned dosage of lenvatinib during Cycle 1 as a result of treatment-related failure.

    Time frame: Cycle 1 (4 weeks) of each dose level

  3. Treatment-Related Adverse Events (All Grades) With an Overall Incidence Greater Than or Equal to 10%

    Treatment-related AEs were untoward medical events that were considered by the investigator to be possibly or probably related to lenvatinib.

    Time frame: First date of study treatment to date of withdrawal from study or last dose of study treatment, up to approximately 13 years and 8 months

  4. Best Overall Response (BOR)

    BOR was the best confirmed response of complete response (CR), partial response (PR), progressive disease (PD), stable disease (SD), or not evaluable (NE), recorded from the start of lenvatinib until disease progression/recurrence or death. CR; disappearance of all target lesions for at least 1 month. PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD; a 20% or greater increase in the sum of the longest diameter of measured lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions. SD; PR failed to be achieved in the overall response assessment and there was no PD observed at 7 weeks or later after starting lenvatinib.

    Time frame: Baseline to first date of documented CR, PR, SD, or PD, assessed up to approximately 4 years

  5. Maximum Plasma Concentration (Cmax) of Lenvatinib

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  6. Time to Maximum Plasma Concentration (Tmax) of Lenvatinib

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  7. Apparent Plasma Half-life (t1/2) of Lenvatinib

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  8. Area Under the Plasma Concentration Curve From Time 0 to Infinity (AUC(0-inf))

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  9. Area Under the Plasma Concentration Curve From Time 0 to 24 Hours (AUC(0-24))

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  10. Clearance Corrected for the Fraction of Lenvatinib Absorbed (CL/F)

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  11. Apparent Volume of Distribution (Vz/F)

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  12. Fraction of Unchanged Lenvatinib Excreted in the Urine (fe)

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  13. Renal Clearance (CLr) of Lenvatinib

    Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)

  14. Effect of Food on the Area Under the Curve From Zero to 24 Hours (AUC(0-24))

    Time frame: Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)

  15. Effect of Food on the Maximum Plasma Concentration (Cmax) of Lenvatinib

    Time frame: Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)

  16. Effect of Food on Time to Maximum Concentration (Tmax) of Lenvatinib

    Time frame: Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)

Other outcomes

  1. Pharmacodynamic (PD) Biomarkers of Lenvatinib in Peripheral Blood Mononuclear Cells (PBMCs) and Tumor Samples

    Based on the data in assay development stage before PD biomarker analysis in study E7080-E044-101 we did not find the appropriate PD biomarker in PBMC, therefore we did not have any biomarker analysis for PK/PD analysis.

    Time frame: Blood: Cycle 1 Day 1, Day 15, or Day 22, Cycle 2 Day 1 Tumor tissue: Screening and after at least one 28-day Cycle of study treatment

07

Results

Posted May 27, 2016

Participant flow

Participants took part in the study at 1 site in United Kingdom and 1 site in Netherlands from 01 July 2005 to 01 March 2019.

Dose Escalation (4 Weeks)
Participant flow — Dose Escalation (4 Weeks)
MilestoneLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib Fasted/Fed 25 mgLenvatinib Fed/Fasted 25 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Started4443331296300247
Completed4443331296300247
Not completed00000000000000
Food-Effect Pilot Study (4 Weeks)
Participant flow — Food-Effect Pilot Study (4 Weeks)
MilestoneLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib Fasted/Fed 25 mgLenvatinib Fed/Fasted 25 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Started00000000006500
Completed00000000006500
Not completed00000000000000

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

The MTD was defined as the highest dose level at which no more than one out of six participants experienced dose-limiting toxicity (DLT). DLT was assessed during the first 4 weeks of therapy (Cycle 1) for dose escalation purposes. Participants enrolled into the MTD cohort were given the option to also participate in the food-effect pilot study. The food-effect pilot study was initiated once the MTD had been established.

Time frame:
Cycle 1 (4 weeks)
Reported as:
Number · milligram (mg)
Maximum Tolerated Dose (MTD)
milligram (mg)Lenvatinib
Maximum Tolerated Dose (MTD)25
SecondarySummary of Adverse Events (AEs) and Serious Adverse Events (SAEs)

All AEs were graded on a 5-point scale according to the National Cancer Institute's Common Toxicity Criteria (NCI CTC) grading system, version 3.0. Safety was assessed using the occurrence of DLTs, AEs, SAEs, clinical laboratory test results, vital signs measurements, physical examination findings, and electrocardiograms (ECGs) readings. An AE was defined as any untoward medical occurrence in a participant administered lenvatinib and did not necessarily have a causal relationship to lenvatinib. An SAE was defined as any untoward medical occurrence which results in death, was life-threatening, required hospitalization or prolonged hospitalization, resulted in persistent or significant disability/incapacity, or caused a congenital anomaly/birth defect. Treatment-related AEs and SAEs are AEs considered probably or possibly related to lenvatinib.

Time frame:
First date of study treatment to date of last dose of study treatment, up to approximately 13 years and 8 months
Reported as:
Number · Percentage of participants
Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participantsLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib Fasted/Fed 25 mgLenvatinib Fed/Fasted 25 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Adverse events100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Treatment-related adverse events75.075.050.066.7100.0100.091.7100.0100.0100.0100.0100.0100.085.7
Serious adverse events50.050.025.033.30100.041.744.433.3100.033.340.062.542.9
Treatment-related serious adverse events25.0025.00033.38.311.133.366.716.720.033.314.3
SecondaryDose-limiting Toxicities (DLTs)

A DLT was defined as any grade 3 or higher hematological or non-hematological toxicity directly related to lenvatinib, any repeated National Cancer Institute Common Toxicity Criteria (NCI CTC) grade 2 hematological or non-hematological toxicity considered to be directly related to lenvatinib and required dose reduction, or failure to administer greater than or equal to 75% of the planned dosage of lenvatinib during Cycle 1 as a result of treatment-related failure.

Time frame:
Cycle 1 (4 weeks) of each dose level
Reported as:
Number · Participants
Dose-limiting Toxicities (DLTs)
ParticipantsLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Febrile neutropenia000001000000
Proteinuria000000010002
Thrombocytopenia000000010000
Hypertension000000001000
Fatigue000000001000
SecondaryTreatment-Related Adverse Events (All Grades) With an Overall Incidence Greater Than or Equal to 10%

Treatment-related AEs were untoward medical events that were considered by the investigator to be possibly or probably related to lenvatinib.

Time frame:
First date of study treatment to date of withdrawal from study or last dose of study treatment, up to approximately 13 years and 8 months
Reported as:
Number · Percentage of participants
Treatment-Related Adverse Events (All Grades) With an Overall Incidence Greater Than or Equal to 10%
Percentage of participantsLenvatinib 0.2 - 6.4 mgLenvatinib 12 - 20 mgLenvatinib 25 mgLenvatinib 32 mg
Hypertension10406357
Nausea38175843
Diarrhoea19275057
Stomatitis5206357
Proteinuria14272943
Vomiting33103314
Lethargy14173829
Dysphonia0134643
Dry skin5104614
Fatigue10232114
Anorexia10172129
Constipation10103314
Headache072929
Abdominal pain07290
SecondaryBest Overall Response (BOR)

BOR was the best confirmed response of complete response (CR), partial response (PR), progressive disease (PD), stable disease (SD), or not evaluable (NE), recorded from the start of lenvatinib until disease progression/recurrence or death. CR; disappearance of all target lesions for at least 1 month. PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD; a 20% or greater increase in the sum of the longest diameter of measured lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions. SD; PR failed to be achieved in the overall response assessment and there was no PD observed at 7 weeks or later after starting lenvatinib.

Time frame:
Baseline to first date of documented CR, PR, SD, or PD, assessed up to approximately 4 years
Reported as:
Number · Percentage of participants
Best Overall Response (BOR)
Percentage of participantsLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Partial response000000011.1033.312.528.6
Stable disease0025.033.366.7033.355.683.333.366.742.9
Progressive disease50.050.000033.341.711.116.708.30
Not evaluable25.0000008.300000
SecondaryMaximum Plasma Concentration (Cmax) of Lenvatinib
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · Nanogram per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) of Lenvatinib
Nanogram per milliliter (ng/mL)Lenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 10.753 ± 0.21761.740 ± 0.69214.255 ± 1.747420.967 ± 11.674149.883 ± 15.9952127.067 ± 91.3320259.990 ± 108.1789209.004 ± 112.0090375.077 ± 158.1811408.797 ± 105.6923630.589 ± 234.1659649.927 ± 237.7462
Cycle 2 Day 12.385 ± 0.51625.477 ± 1.59889.610 ± 2.319336.483 ± 10.933992.137 ± 29.0365197.217 ± 136.7307291.414 ± 146.1972187.467 ± 86.3962368.937 ± 148.8160238.670 ± NA544.718 ± 183.1259562.416 ± 121.4056
SecondaryTime to Maximum Plasma Concentration (Tmax) of Lenvatinib
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · Hours
Time to Maximum Plasma Concentration (Tmax) of Lenvatinib
HoursLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 14.280 ± 1.4405.785 ± 2.5693.263 ± 1.1943.973 ± 3.4949.557 ± 12.6582.023 ± 1.0352.348 ± 1.1441.897 ± 0.77682.287 ± 0.38812.533 ± 0.8261.770 ± 0.7152.674 ± 2.038
Cycle 2 Day 12.225 ± 0.38892.680 ± 0.58913.475 ± 14.8142.360 ± 1.1792.173 ± 0.5832.103 ± 0.4052.021 ± 1.2951.944 ± 0.6042.352 ± 0.7053.000 ± NA2.983 ± 1.4811.500 ± 0.408
SecondaryApparent Plasma Half-life (t1/2) of Lenvatinib
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · Hours
Apparent Plasma Half-life (t1/2) of Lenvatinib
HoursLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 1——18.180 ± 11.34210.695 ± 8.78912.805 ± 3.1188.077 ± 0.7495.981 ± 0.48406.567 ± 0.95537.115 ± 1.08666.960 ± 1.2305.848 ± 1.0185.550 ± 0.599
Cycle 2 Day 129.540 ± 8.273126.380 ± 8.042720.840 ± NA10.827 ± 5.5559.973 ± 1.2888.330 ± 0.5176.935 ± 1.16816.829 ± 1.0196.935 ± 0.93138.090 ± NA6.025 ± 0.7046.675 ± 0.5216
SecondaryArea Under the Plasma Concentration Curve From Time 0 to Infinity (AUC(0-inf))
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration Curve From Time 0 to Infinity (AUC(0-inf))
nanogram*hour per milliliter (ng*hr/mL)Lenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 1——123.745 ± 20.810376.645 ± 312.1240780.275 ± 189.1161335.493 ± 894.5621895.454 ± 467.1451693.298 ± 1011.79413683.590 ± 2210.45214238.680 ± 2602.92714413.263 ± 1946.5714383.678 ± 1697.248
Cycle 2 Day 199.325 ± 0.1202174.310 ± 46.259370.390 ± NA585.247 ± 397.9091150.393 ± 192.3651952.430 ± 1323.7832278.016 ± 851.2581558.101 ± 760.6873310.673 ± 1544.7082260.040 ± NA4549.825 ± 1161.0454391.160 ± 997.486
SecondaryArea Under the Plasma Concentration Curve From Time 0 to 24 Hours (AUC(0-24))
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration Curve From Time 0 to 24 Hours (AUC(0-24))
ng*hr/mLLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 114.348 ± 4.50030.207 ± 14.52161.915 ± 17.164220.910 ± 129.838659.553 ± 209.1291168.257 ± 799.1691655.035 ± 555.4791537.476 ± 876.68053250.843 ± 1826.87893709.550 ± 2059.63794074.803 ± 1666.27804601.014 ± 1887.3642
Cycle 2 Day 143.305 ± 8.591385.477 ± 37.054199.100 ± NA422.873 ± 270.528931.307 ± 179.5141691.160 ± 1167.7502052.965 ± 789.5041422.584 ± 697.6992947.920 ± 1286.8051934.500 ± NA4224.095 ± 1120.8374020.185 ± 899.182
SecondaryClearance Corrected for the Fraction of Lenvatinib Absorbed (CL/F)
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · Liter per hour (L/hr)
Clearance Corrected for the Fraction of Lenvatinib Absorbed (CL/F)
Liter per hour (L/hr)Lenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 1——6.560 ± 1.1036.470 ± 5.3604.225 ± 1.02538.190 ± 7.9236.614 ± 1.3369.534 ± 4.3076.157 ± 4.2405.980 ± 3.2366.863 ± 3.3548.827 ± 5.058
Cycle 2 Day 14.710 ± 0.93345.200 ± 1.8024.020 ± NA5.347 ± 3.9423.533 ± 0.7475.557 ± 4.2006.896 ± 3.36010.110 ± 3.3216.437 ± 3.66810.340 ± NA6.378 ± 2.3027.978 ± 2.763
SecondaryApparent Volume of Distribution (Vz/F)
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · Liter (L)
Apparent Volume of Distribution (Vz/F)
Liter (L)Lenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 1——162.975 ± 78.38365.795 ± 0.643580.365 ± 37.92297.190 ± 95.44257.039 ± 11.88788.069 ± 38.17458.408 ± 32.34656.350 ± 22.93255.263 ± 22.41168.073 ± 32.456
Cycle 2 Day 1206.360 ± 96.068208.937 ± 114.969120.810 ± NA65.437 ± 24.89451.487 ± 16.80567.747 ± 51.89770.881 ± 40.41999.960 ± 37.78760.683 ± 26.763120.730 ± NA57.143 ± 28.55076.610 ± 25.967
SecondaryFraction of Unchanged Lenvatinib Excreted in the Urine (fe)
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · Percentage of lenvatinib
Fraction of Unchanged Lenvatinib Excreted in the Urine (fe)
Percentage of lenvatinibLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 10.530 ± 0.01410.253 ± 0.04570.217 ± 0.08960.363 ± 0.12900.355 ± 0.03540.390 ± 0.08490.487 ± 0.31370.783 ± 0.79280.348 ± 0.19100.690 ± 0.48510.576 ± 0.30420.503 ± 0.3004
Cycle 2 Day 11.240 ± NA0.715 ± 0.16260.605 ± 0.06360.535 ± 0.37481.050 ± NA0.557 ± 0.22120.689 ± 0.42080.663 ± 0.28730.825 ± 0.27860.630 ± NA0.778 ± 0.38010.527 ± 0.1595
SecondaryRenal Clearance (CLr) of Lenvatinib
Time frame:
Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · L/hour
Renal Clearance (CLr) of Lenvatinib
L/hourLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Cycle 1 Day 10.060 ± 0.00640.037 ± 0.01670.027 ± 0.00420.035 ± 0.02330.021 ± 0.01130.017 ± 0.00780.039 ± 0.02430.064 ± 0.05340.020 ± 0.00950.046 ± 0.04660.041 ± 0.02330.035 ± 0.0144
Cycle 2 Day 10.050 ± NA0.045 ± 0.0110.022 ± NA0.029 ± 0.00420.034 ± NA0.025 ± 0.00970.050 ± 0.03040.069 ± 0.0210.048 ± 0.360.065 ± NA0.52 ± 0.0190.045 ± 0.0247
SecondaryEffect of Food on the Area Under the Curve From Zero to 24 Hours (AUC(0-24))
Time frame:
Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · ng*hr/mL
Effect of Food on the Area Under the Curve From Zero to 24 Hours (AUC(0-24))
ng*hr/mLLenvatinib Fed 25 mgLenvatinib Fasted 25 mg
Effect of Food on the Area Under the Curve From Zero to 24 Hours (AUC(0-24))3851.773 ± 993.14494039.681 ± 1567.4169
SecondaryEffect of Food on the Maximum Plasma Concentration (Cmax) of Lenvatinib
Time frame:
Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Mean · ng/mL
Effect of Food on the Maximum Plasma Concentration (Cmax) of Lenvatinib
ng/mLLenvatinib Fed 25 mgLenvatinib Fasted 25 mg
Effect of Food on the Maximum Plasma Concentration (Cmax) of Lenvatinib508.558 ± 165.7591544.058 ± 248.5409
SecondaryEffect of Food on Time to Maximum Concentration (Tmax) of Lenvatinib
Time frame:
Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)
Reported as:
Median · Hours
Effect of Food on Time to Maximum Concentration (Tmax) of Lenvatinib
HoursLenvatinib Fed State 25 mgLenvatinib Fasted State 25 mg
Effect of Food on Time to Maximum Concentration (Tmax) of Lenvatinib4.980 (2.00 to 5.07)2.030 (1.00 to 3.07)
Statistical analysis
  • Lenvatinib Fed State 25 mg vs Lenvatinib Fasted State 25 mg · Wilcoxon signed-rank test · p = 0.0146
Other pre-specifiedPharmacodynamic (PD) Biomarkers of Lenvatinib in Peripheral Blood Mononuclear Cells (PBMCs) and Tumor Samples

Based on the data in assay development stage before PD biomarker analysis in study E7080-E044-101 we did not find the appropriate PD biomarker in PBMC, therefore we did not have any biomarker analysis for PK/PD analysis.

Time frame:
Blood: Cycle 1 Day 1, Day 15, or Day 22, Cycle 2 Day 1 Tumor tissue: Screening and after at least one 28-day Cycle of study treatment

No measurements were reported for this outcome.

Adverse events

Collected over All adverse events (AEs) were collected for up to approximately 13 years and 8 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 0.2 mg0/4 (0%)2/4 (50%)4/4 (100%)
Lenvatinib 0.4 mg1/4 (25%)2/4 (50%)4/4 (100%)
Lenvatinib 0.8 mg1/4 (25%)1/4 (25%)4/4 (100%)
Lenvatinib 1.6 mg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Lenvatinib 3.2 mg0/3 (0%)0/3 (0%)3/3 (100%)
Lenvatinib 6.4 mg2/3 (66.7%)3/3 (100%)3/3 (100%)
Lenvatinib 12 mg1/12 (8.3%)5/12 (41.7%)12/12 (100%)
Lenvatinib 12.5 mg1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Lenvatinib 16 mg1/6 (16.7%)2/6 (33.3%)6/6 (100%)
Lenvatinib 20 mg3/3 (100%)3/3 (100%)3/3 (100%)
Lenvatinib Fasted/Fed 25 mg0/6 (0%)2/6 (33.3%)6/6 (100%)
Lenvatinib Fed/Fasted 25 mg0/5 (0%)2/5 (40%)5/5 (100%)
Lenvatinib (MTD Cohort) 25 mg3/24 (12.5%)15/24 (62.5%)24/24 (100%)
Lenvatinib 32 mg2/7 (28.6%)3/7 (42.9%)6/7 (85.7%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib Fasted/Fed 25 mgLenvatinib Fed/Fasted 25 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
Abdominal painGastrointestinal disorders0/40/40/40/30/31/31/120/90/60/30/60/53/240/7
VomitingGastrointestinal disorders0/41/40/40/30/31/30/120/90/60/30/60/53/240/7
DiarrhoeaGastrointestinal disorders0/40/40/40/30/30/30/120/90/61/30/60/51/240/7
HaematemesisGastrointestinal disorders0/40/40/40/30/30/30/120/90/61/30/60/50/240/7
MelaenaGastrointestinal disorders0/40/40/40/30/30/30/120/90/61/30/60/50/240/7
PyrexiaGeneral disorders0/41/40/40/30/31/30/121/90/60/30/61/51/240/7
General physical health deteriorationGeneral disorders0/40/40/41/30/31/30/120/90/61/30/60/50/240/7
MalaiseGeneral disorders0/40/40/40/30/30/30/120/90/61/30/60/50/240/7
Lower respiratory tract infectionInfections and infestations0/40/40/40/30/30/30/120/90/61/30/60/50/241/7
InfectionInfections and infestations0/40/40/40/30/30/30/120/90/61/30/60/50/240/7
Most frequent other events
Showing 10 of 213
Most frequent other events
EventLenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib Fasted/Fed 25 mgLenvatinib Fed/Fasted 25 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mg
NauseaGastrointestinal disorders1/43/42/42/33/32/33/122/92/63/34/65/517/243/7
DiarrhoeaGastrointestinal disorders1/42/41/41/32/30/33/123/93/63/35/64/516/244/7
VomitingGastrointestinal disorders1/42/41/41/33/30/34/124/91/62/31/64/513/241/7
StomatitisGastrointestinal disorders0/41/40/40/31/31/33/122/93/61/35/63/515/244/7
DyspnoeaRespiratory, thoracic and mediastinal disorders1/41/43/41/30/30/30/123/91/61/31/61/55/243/7
DyspepsiaGastrointestinal disorders1/40/40/40/30/30/31/120/90/62/31/61/54/240/7
ToothacheGastrointestinal disorders0/40/40/40/30/32/30/122/90/60/31/60/51/240/7
LethargyNervous system disorders1/41/40/41/32/31/33/123/91/60/31/60/510/242/7
FatigueGeneral disorders1/40/40/41/30/31/33/123/92/61/34/62/58/243/7
PyrexiaGeneral disorders0/41/40/41/32/30/31/120/90/62/32/63/57/241/7

Baseline characteristics

Intent-to-treat (ITT) population included all participants who received at least one dose of lenvatinib.

Age, Continuous
Age, Continuous(Years)Lenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mgTotal
Mean64.5 ± 7.9447.8 ± 6.4564.0 ± 6.4860.0 ± 11.5365.0 ± 19.0051.0 ± 22.7246.3 ± 13.2552.6 ± 13.2855.7 ± 13.3251.7 ± 12.3452.2 ± 9.6553.9 ± 11.8453.4 ± 12.32
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 0.2 mgLenvatinib 0.4 mgLenvatinib 0.8 mgLenvatinib 1.6 mgLenvatinib 3.2 mgLenvatinib 6.4 mgLenvatinib 12 mgLenvatinib 12.5 mgLenvatinib 16 mgLenvatinib 20 mgLenvatinib (MTD Cohort) 25 mgLenvatinib 32 mgTotal
Female232120833014139
Male212213463310643
08

Study locations

2 sites
  • Netherlands Cancer Institute- Antoni Van Leeuwenhoek Hospital
    Amsterdam, 1066 Cx, Netherlands
  • Gartnavel General Hospital
    Glasgow, G12 0Yn, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Jun 2009, 47 months.

Results were first posted in May 2016, 6 years 11 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 47 months is close to that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2005
First posted
Jul 21, 2005
StartActual
Jul 1, 2005
Primary completionActual
Jun 19, 2009
CompletionActual
Mar 1, 2019
Results first posted
May 27, 2016
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00121719
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jul 21, 2005
Start date
Jul 1, 2005
Primary completion
Jun 19, 2009
Completion
Mar 1, 2019
Results posted
May 27, 2016
Last update
Jun 22, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion